Physician
Mclaren Oakland
Mclaren Oakland was paid $5.73M by Medicaid between Jan 2018 and Dec 2024, across 128 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 35% of everything it billed.
33Billing provider infoMCLAREN OAKLAND
PONTIAC, MI 48342
PONTIAC, MI 48342
33aNPI1053463778assigned 01/16/2007
33bProvider typeDermatology Physician
28Total paid$5.73M
24GClaims163,145
24DCodes billed128
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Dermatology Physician providers in Michigan
Rank by total paid#3 of 51
Median peer was paid$67K
This provider vs. median86×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 14,499 | $565K | |
| 2019 | 37,427 | $449K | |
| 2020 | 25,207 | $435K | |
| 2021 | 24,607 | $1.16M | |
| 2022 | 22,257 | $1.15M | |
| 2023 | 23,369 | $1.19M | |
| 2024incomplete | 15,779 | $772K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 35% | 30,156 | 28,223 | $2.01M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 25% | 34,587 | 31,432 | $1.43M |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 5.6% | 4,007 | 3,659 | $323K |
| 99223 | Prolong inpt eval add15 m | 4.8% | 2,807 | 2,577 | $273K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 4.3% | 2,883 | 2,851 | $244K |
| 99232 | Hospital visit by a doctor, follow-up daySubsequent hospital care, per day, moderate complexity | 3.3% | 5,066 | 2,131 | $191K |
| 99233 | Hospital visit by a doctor, follow-up day (complex)Prolong inpt eval add15 m | 2.2% | 2,577 | 902 | $129K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 2.2% | 2,415 | 2,322 | $128K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | 2.1% | 1,348 | 1,330 | $120K |
| 99205 | Prolong outpt/office vis | 1.8% | 988 | 979 | $105K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 1.5% | 1,544 | 1,421 | $86K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.3% | 2,112 | 2,098 | $77K |
116 more codes
| 99284 | Emergency room visit (serious) | 1.3% | 1,365 | $75K |
| 99285 | Emergency room visit (most serious) | 1.2% | 1,042 | $69K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 1.2% | 860 | $68K |
| 99222 | Initial hospital care, per day, moderate complexity | 1.2% | 929 | $67K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 1.1% | 14,088 | $62K |
| 62323 | <1% | 884 | $52K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 1,325 | $18K |
| 80053 | Comprehensive metabolic panel | <1% | 4,575 | $15K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 122 | $14K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,917 | $13K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 573 | $13K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 480 | $10K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,192 | $10K |
| 20610 | <1% | 408 | $10K | |
| 80061 | Lipid panel | <1% | 3,432 | $9K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 6,509 | $9K |
| 58662 | <1% | 140 | $8K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,398 | $8K |
| 93970 | <1% | 339 | $6K | |
| 93000 | <1% | 803 | $6K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 193 | $5K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 665 | $5K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 611 | $5K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 70 | $5K |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,674 | $5K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,486 | $4K |
| 99152 | <1% | 455 | $3K | |
| 84439 | <1% | 1,283 | $2K | |
| 82728 | <1% | 858 | $2K | |
| 87390 | <1% | 429 | $2K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 30 | $2K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 24 | $2K |
| 93018 | <1% | 240 | $2K | |
| 82607 | <1% | 593 | $2K | |
| 27096 | <1% | 19 | $1K | |
| 99385 | <1% | 13 | $1K | |
| 83550 | <1% | 786 | $1K | |
| 86702 | <1% | 436 | $1K | |
| 99496 | <1% | 12 | $1K | |
| 93971 | <1% | 88 | $1K | |
| 83540 | <1% | 907 | $1K | |
| 90686 | <1% | 61 | $993.29 | |
| 87070 | <1% | 512 | $870.55 | |
| 64493 | <1% | 12 | $870.24 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 567 | $836.56 |
| 93308 | <1% | 67 | $836.04 | |
| 80074 | <1% | 133 | $796.40 | |
| 99443 | <1% | 38 | $763.74 | |
| 99221 | <1% | 16 | $743.03 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 232 | $631.31 |
| 82565 | <1% | 935 | $569.43 | |
| 58661 | <1% | 12 | $551.62 | |
| G0008 | Administration of influenza virus vaccine | <1% | 46 | $551.00 |
| 96160 | <1% | 29 | $518.97 | |
| 85610 | <1% | 754 | $512.73 | |
| 64495 | <1% | 12 | $509.32 | |
| 93356 | <1% | 59 | $506.70 | |
| 64494 | <1% | 12 | $502.62 | |
| 84450 | <1% | 837 | $484.80 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 308 | $475.07 |
| 84460 | <1% | 829 | $470.62 | |
| 86038 | <1% | 260 | $449.89 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 94 | $433.39 |
| 84520 | <1% | 895 | $428.23 | |
| 80051 | <1% | 622 | $414.24 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 13 | $392.33 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 15 | $382.32 |
| 81003 | <1% | 454 | $378.89 | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 15 | $357.86 |
| 93298 | <1% | 24 | $342.82 | |
| 85027 | <1% | 307 | $336.95 | |
| 83735 | <1% | 308 | $326.70 | |
| 82043 | <1% | 322 | $264.88 | |
| 82947 | <1% | 552 | $262.00 | |
| 93880 | <1% | 12 | $217.75 | |
| 84436 | <1% | 160 | $188.77 | |
| 90688 | <1% | 12 | $177.41 | |
| 99442 | <1% | 14 | $170.47 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 15 | $154.28 |
| 84153 | <1% | 90 | $148.52 | |
| 86803 | <1% | 53 | $147.12 | |
| 85652 | <1% | 411 | $141.15 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 19 | $127.48 |
| 82570 | <1% | 206 | $115.24 | |
| 86140 | <1% | 205 | $112.79 | |
| 99406 | <1% | 12 | $97.13 | |
| 84481 | <1% | 106 | $74.48 | |
| 86592 | <1% | 119 | $70.33 | |
| 86431 | <1% | 150 | $57.96 | |
| 87186 | <1% | 147 | $53.29 | |
| 87077 | <1% | 160 | $49.70 | |
| 84550 | <1% | 12 | $31.20 | |
| 82746 | <1% | 100 | $21.92 | |
| 82248 | <1% | 12 | $19.10 | |
| 81001 | <1% | 93 | $15.18 | |
| 82247 | <1% | 17 | $11.01 | |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 26 | $7.33 |
| 99153 | Mod sedat endo service >5yrs | <1% | 34 | $6.14 |
| 85046 | <1% | 14 | $4.07 | |
| 83690 | <1% | 44 | $3.80 | |
| 81002 | 0% | 293 | $0.00 | |
| 3078F | 0% | 260 | $0.00 | |
| 1160F | 0% | 14 | $0.00 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 0% | 18 | $0.00 |
| 3079F | 0% | 291 | $0.00 | |
| 1111F | 0% | 35 | $0.00 | |
| 1101F | 0% | 12 | $0.00 | |
| 3074F | 0% | 446 | $0.00 | |
| 3044F | 0% | 102 | $0.00 | |
| 3075F | 0% | 61 | $0.00 | |
| 3008F | 0% | 84 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 16 | $0.00 |
| 82150 | 0% | 55 | $0.00 | |
| 82962 | 0% | 93 | $0.00 | |
| 4010F | 0% | 14 | $0.00 | |
| 3061F | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMARCOTTE, LYNN (VP/CFO)
| Provider | Location | Paid |
|---|---|---|
| Mclaren Oakland | Pontiac, MI | $39.12M |
| Mclaren Oakland | Pontiac, MI | $2.33M |
| Mclaren Oakland | Pontiac, MI | $478K |
| Mclaren Oakland | Pontiac, MI | $7K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.